Efficacy and safety of once-weekly semaglutide versus exenatide er in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label
B12 is not a weight loss drug, but it can help people feel less tired, which makes it easier to be physically active and manage a healthy lifestyle
That's what produces the dramatic appetite reduction and 1522% body weight loss seen in tirzepatide's clinical trials
This protective effect is attributed not only to their influence on systemic metabolism, which safeguards the heart, but also to their direct actions on cardiac tissues
Zimmermann T, Hueppe D, Mauss S, Buggisch P, Pfeiffer-Vornkahl H, Grimm D, et al
Mayo B, Vazquez L, Florez AB